EXELTIS USA INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELTIS USA INC, and what generic alternatives to EXELTIS USA INC drugs are available?
EXELTIS USA INC has four approved drugs.
There are fifteen US patents protecting EXELTIS USA INC drugs.
There are fifty-six patent family members on EXELTIS USA INC drugs in twenty-nine countries and fifty-eight supplementary protection certificates in fourteen countries.
Summary for EXELTIS USA INC
| International Patents: | 56 |
| US Patents: | 15 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for EXELTIS USA INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 10,179,140 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 11,504,334 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | 10,603,281 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EXELTIS USA INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | ESTRASORB | estradiol hemihydrate | EMULSION;TOPICAL | 021371-001 | Oct 9, 2003 | 5,629,021 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EXELTIS USA INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| France | 22C1031 | ⤷ Subscribe |
| Lithuania | PA2021523 | ⤷ Subscribe |
| Hungary | S2000016 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EXELTIS USA INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0398460 | 04C0022 | France | ⤷ Subscribe | PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211 |
| 2588114 | 2020C/518 | Belgium | ⤷ Subscribe | PRODUCT NAME: DROSPIRENON; AUTHORISATION NUMBER AND DATE: BE548284 20191107 |
| 3632448 | C202230031 | Spain | ⤷ Subscribe | PRODUCT NAME: DROSPIRENONA; NATIONAL AUTHORISATION NUMBER: 84603-SE/H/1869/001/DC; DATE OF AUTHORISATION: 20191025; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SE/H/1809/001/DC; DATE OF FIRST AUTHORISATION IN EEA: 20191016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
